Patent
Selecting patients for therapy with a her inhibitor
Lukas C. Amler,Thomas Januario +1 more
Reads0
Chats0
TLDR
A method for selecting patients for therapy with a HER inhibitor, such as pertuzumab, based on gene expression analysis is described in this article, and a method for assessing HER phosphorylation or activation in a biological sample via gene expression analyses is also described.Abstract:
A method for selecting patients for therapy with a HER inhibitor, such as pertuzumab, based on gene expression analysis is described. A method for assessing HER phosphorylation or activation in a biological sample via gene expression analysis is also described.read more
Citations
More filters
Patent
HER2 antibody composition
TL;DR: In this article, a composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed.
Patent
Treatment of metastatic breast cancer
TL;DR: In this article, a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane was used for the treatment of previously untreated HER2-positive metastatic breast cancer.
Patent
Specific binding proteins and uses thereof
Lloyd J. Old,Terrance Grant Johns,Con Panousis,Andrew M. Scott,Christoph Renner,Gred Ritter,Achim A. Jungbluth,Elisabeth Stockert,V. Peter Collins,Webster K. Cavenee,Huei-Jen Su Huang,Antony W. Burgess,Edouard C. Nice +12 more
TL;DR: In this article, specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR are presented.
Patent
Combination therapy of her expressing tumors
TL;DR: In this article, the HER2-dimerization inhibitors (HDIs) and EGFR inhibitors (EGFR inhibitors) were used to treat tumors expressing HER2 and EGF.
Patent
Antigen-binding proteins
TL;DR: In this article, the linkers suitable for use in antigen-binding proteins, certain antigen binding proteins and methods of making such proteins and uses thereof are described and discussed. But the authors do not discuss the use of linkers in specific applications.
References
More filters
Patent
Method for making humanized antibodies
Paul Carter,Leonard G. Presta +1 more
TL;DR: In this article, the authors provide a detailed discussion of the use of humanized antibody polypeptides and methods for their preparation and use, along with consensus immunoglobulin sequences and structural models.
Journal ArticleDOI
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Matthew C. Franklin,Kendall D. Carey,Felix Vajdos,Daniel J. Leahy,Abraham M. de Vos,Mark X. Sliwkowski +5 more
TL;DR: The 3.2 A X-ray crystal structure of the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2 or HER2) in a complex with the antigen binding fragment of pertuzumab, an anti-Erb B2 monoclonal antibody, is determined.
Patent
Humanized antibodies and methods for making them
Paul Carter,Leonard G. Presta +1 more
TL;DR: In this paper, the authors provide a detailed discussion of the use of humanized antibody polypeptides and methods for their preparation and use, along with consensus immunoglobulin sequences and structural models.
Journal ArticleDOI
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
David B. Agus,Robert W. Akita,William D. Fox,Gail D. Lewis,Brian Higgins,Paul I. Pisacane,Julie A. Lofgren,Charles A. Tindell,Douglas P Evans,Krista Maiese,Howard I. Scher,Mark X. Sliwkowski +11 more
TL;DR: It is demonstrated that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment, which sterically hinders ErbB2's recruitment intoErbB ligand complexes.
Patent
Monoclonal antibodies directed to the HER2 receptor
TL;DR: In this article, a method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed.